Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study - Wikidata - wikimedia - TriplyDB

Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study

Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study

http://www.wikidata.org/entity/Q36543833

about

Integrated therapy for HIV and cryptococcosis HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings Preheating of urine improves the specificity of urinary cryptococcal antigen testing using the lateral flow assay.Risk Factors for Cryptococcal Meningitis: A Single United States Center Experience.Evolution of Cryptococcal Antigen Testing: What is new?Accelerating the Uptake and Timing of Antiretroviral Therapy Initiation in Sub-Saharan Africa: An Operations Research Agenda Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized Estimating the cost-per-result of a national reflexed Cryptococcal antigenaemia screening program: Forecasting the impact of potential HIV guideline changes and treatment goals.The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).High Treatment Success Rates Among HIV-Infected Multidrug-Resistant Tuberculosis Patients After Expansion of Antiretroviral Therapy in Botswana, 2006-2013.Point-of-Care Testing for Cryptococcal Disease Among Hospitalized Human Immunodeficiency Virus-Infected Adults in Ethiopia.Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program.High Cryptococcal Antigen Titers in Blood are Predictive of Subclinical Cryptococcal Meningitis Among HIV-Infected Patients.CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis.Cryptococcal Antigen Screening in Asymptomatic HIV-Infected Antiretroviral Naïve Patients in Cameroon and Evaluation of the New Semi-Quantitative Biosynex CryptoPS Test.The war on cryptococcosis: A Review of the antifungal arsenal.Diagnostic and therapeutic strategies in cryptococcosis: impact on outcome.Cryptococcal antigen positivity combined with the percentage of HIV-seropositive samples with CD4 counts <100 cells/μl identifies districts in South Africa with advanced burden of disease.Burden of Fungal Infections in Colombia.

P2860

Q28077707-E4F8F9DF-3B14-401A-8413-FABDB20ACB1F Q28078958-4164E3BC-ABDF-41E9-A1E2-F799CDA827C4 Q33663275-EBA2E588-5970-44DC-9D78-A3193E936148 Q36097979-A9FF7389-3FEB-4CB2-A02A-4DCFADCBC55F Q36873953-AC7E1F4B-0119-446E-BFEA-9C4144739AE0 Q37162105-74D140C1-F83F-4B64-A0C4-FCC78C959D80 Q37393668-E4FDEAB2-9B9C-4693-AE86-DF37C9297F0E Q38614177-3B4C87EE-7903-442D-9412-13C0AADA1AA6 Q39189670-E0FCA012-EB6C-4BF3-B5F2-9231CFBCAE64 Q39463170-EEFACF42-F76C-428B-A51C-1863CED77F0C Q40092528-3612BC20-ED7E-4379-B181-DB4A50867865 Q45326483-6B3E2AC2-535C-40E9-898B-A3CD76DBCE20 Q46801174-4C84F3DE-2428-47EB-B1CD-E2B48EB703C7 Q51365549-882CB801-FE39-43EE-9246-9DD2895B0F9F Q52624536-5600D92C-2725-401A-AB2C-011B60E40B11 Q54260674-81A1510C-9696-4D34-9855-EE089409284E Q55229762-EB3A05FE-8FED-4D7A-A8E4-5826A00FB46A Q55396875-8700285F-5EE3-4CE7-B8EA-35C1EACD4F52 Q55422790-DCFE7F10-1ADA-40E7-8344-1405E80ECCC4

P2860

Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study

http://www.wikidata.org/entity/Q36543833

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Cryptococcal Antigen Screening ...... ca: A Prospective Cohort Study

@ast

Cryptococcal Antigen Screening ...... ca: A Prospective Cohort Study

@en

type

label

Cryptococcal Antigen Screening ...... ca: A Prospective Cohort Study

@ast

Cryptococcal Antigen Screening ...... ca: A Prospective Cohort Study

@en

prefLabel

Cryptococcal Antigen Screening ...... ca: A Prospective Cohort Study

@ast

Cryptococcal Antigen Screening ...... ca: A Prospective Cohort Study

@en

P1433

Q36543833-D9454AE4-EA87-47D5-8D61-7D9D7183DCA1

P1476

Q36543833-62FCA322-6E04-4292-9790-555E873F160F

P2093

Q36543833-541EF769-1DBD-4422-A126-61E36EC1D740

Q36543833-73343F82-E024-456D-BD95-D2BA0468FE18

Q36543833-9538749B-710C-43FC-82CD-37CD5FEDA31B

Q36543833-A8BEC91D-102B-482A-BC8F-F37A7D086F75

Q36543833-E1BA3683-CEEC-4E8D-8A92-BFE2B21F095B

P2860

Q36543833-058411BF-2912-4DA1-8A6F-070A9E0EDD5E

Q36543833-12870A1D-1ED6-46DD-A1D6-2607922ADEB4

Q36543833-1ACD7D1C-C8A1-463D-AF4B-59A5E55407DD

Q36543833-25E25A1B-B44B-43EE-A915-F3369FB7DFDE

Q36543833-28550E78-0A31-4F06-BBD6-E544ECC9AB2F

Q36543833-2B9E531E-4EE8-4608-AB2A-A7900A59BF5A

Q36543833-2E5156FC-5C46-4B5F-A951-8E7038921765

Q36543833-31935E5A-2793-40A4-AD55-D9B2FB10148C

Q36543833-383532B0-43F7-466D-B033-1EC702875137

Q36543833-3D2B18C9-8B18-4404-9D33-B91792B8688A

P304

Q36543833-BECBDD1F-7811-47B9-AA00-DC80B032F661

P31

Q36543833-2D47E57B-A1DE-4F4B-9A69-197782AABBA1

P356

Q36543833-82359DB6-FB2C-4724-98AD-E8611DDEBD86

P407

Q36543833-C2B70FFE-D93E-4397-AF38-4E6F7753D43C

P433

Q36543833-BF18A07C-0681-4E45-BE12-C387CAEC4543

P478

Q36543833-ED175E22-0319-4ACE-A746-D1C5470D039A

P50

Q36543833-21787CEA-3A88-48B7-A564-32C7C8227625

Q36543833-4B2EFE65-CA32-4A4C-983B-5D37114058AB

Q36543833-7D225E3B-1078-48BB-9791-06C64EA85E4C

Q36543833-B5CED49D-7E2F-4C76-AC88-66040EC1EEA7

Q36543833-C50B9ACC-6D6C-4F0C-97E1-C87968C1E292

P577

Q36543833-01CAD538-E2A9-418C-822B-B68D0BEFE636

P5875

Q36543833-1908DD85-04E5-46D7-BA2A-AE12CABFC5AA

P698

Q36543833-DBA5FA37-BDF9-4A09-8B47-05E59A33DB44

P921

Q36543833-639E39AC-1BAE-434C-8A11-672C96F0D3B6

P932

Q36543833-74D49737-4364-4B2D-A6C0-882615E81631

P356

P1433

Clinical Infectious Diseases

P1476

Cryptococcal Antigen Screening ...... ca: A Prospective Cohort Study

@en

P2093

Anna Cross

http://www.w3.org/2001/XMLSchema#string

Joseph Nicholas Jarvis

http://www.w3.org/2001/XMLSchema#string

Nelesh P Govender

http://www.w3.org/2001/XMLSchema#string

Nicky Longley

http://www.w3.org/2001/XMLSchema#string

Nicola Kelly

http://www.w3.org/2001/XMLSchema#string

P2860

Review of Human Immunodeficiency Virus Type 1–Related Opportunistic Infections in Sub‐Saharan Africa

Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings

Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast

Elucidating the immunological function of the Cryptococcus neoformans capsule

Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases

Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease?

High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out

Point-of-care lateral flow assays for tuberculosis and cryptococcal antigenuria predict death in HIV infected adults in Uganda

P304

581-587

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIV936

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

Linda-Gail Bekker

Graeme Meintjes

Thomas Harrison

P577

2015-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283754020

http://www.w3.org/2001/XMLSchema#string

P698

26565007

http://www.w3.org/2001/XMLSchema#string

P921

Aafrikaa Kibbaa

P932

4741358

http://www.w3.org/2001/XMLSchema#string